Daratumumab, a complement-activating anti-CD38 MoAb capable of causing antibody‐dependent cellular cytotoxicity (ADCC) and apoptosis in MM cells, showed significant single agent activity in relapsed MM patients and improved the survival outcome when used in combination with other active anti-MM agents such as bortezomib and dexamethasone or lenalidomide and dexamethasone (4, 20, 31–34). Here, CD38 is linked to Miyoshi myopathy.